Aclaris Therapeutics, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/705f947d-4266-4baa-bebf-9941768bee03/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $7.8M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-020540 |
| FY 2024 | $18.7M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-001819 |
| FY 2023 | $31.2M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-001753 |
| FY 2022 | $29.8M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-001829 |
| FY 2021 | $6.8M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001838 |
| FY 2020 | $6.5M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001717 |
| FY 2019 | $4.2M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001325 |
| FY 2018 | $6.2M | 2018-01-01 – 2018-12-31 | evidence 0001558370-20-001325 |
| FY 2017 | $1.7M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-002211 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Aclaris Therapeutics, Inc. — all facts · Net Income · Operating Income